In ftRPE cells, SI-D609 cotreatment, each at 10 μM, for 18 h or 24 h yielded viability higher than 95%, compared with under 20% following SI treatment. In SKBr3 cells, D609 at 50 μg/mL produced a 3.5-fold decrease in PC-PLC activity within 1 hour, maintained up to 72 hours. In a fluorescence-based assay using recombinant mouse ACE1 enzyme, D609 had a reported IC50 ± SEM of 31.05 ± 10.82 µM. [1,2,3]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
Cell viability following cotreatment in ftRPE cells
Cell-based study · ftRPE cells [1]
ftRPE cells received SI-D609 cotreatment, each at 10 μM, for 18 h or 24 h. Viability was higher than 95% in the SI-D609 cotreatment group, compared with under 20% following SI treatment.
Literature-Reported Treatment Conditions
- Treatment concentration
- 10 μM
- Exposure duration
- 18 h or 24 h
- Method
- cotreatment
- Co-treatment
- Other interventions in this design: SI 10 μM. Compound effect isolated by the comparison: SI-D609 cotreatment group.
- Reported limits
- Not stated in the sentences used: vehicle.
Methods and source locations
Compound reported in the paper: D609
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Results > D609 inhibited the SI-induced ftRPE necrotic cell death (S24); Materials and methods > CCK8 assay (S113); Fig. 2 legend (S196)
cell viability tested by CCK8-kit: cell viability tested by CCK8-kit; comparator: SI treatment (10 μM) — Results > D609 inhibited the SI-induced ftRPE necrotic cell death (S24); Fig. 2 legend (S196)
PC-PLC activity in SKBr3 cells
Cell-based study · SKBr3 cells [2]
SKBr3 cells were incubated with D609 at 50 μg/mL. PC-PLC activity showed a 3.5-fold decrease within 1 hour, maintained up to 72 hours.
Literature-Reported Treatment Conditions
- Treatment concentration
- 50 μg/mL
- Exposure duration
- within 1 hour and was maintained up to 72 hours
- Method
- cell incubation with D609
- Reported limits
- Not stated in the sentences used: vehicle.
Methods and source locations
Compound reported in the paper: D609
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and methods > In vitro PC-PLC activity assay (S22); Results > PC-PLC inhibition induces downmodulation of HER2 expression on the SKBr3 plasma membrane (S53); Figure 3 legend (S132, S133)
Relative PC-PLC activity: Relative PC-PLC activity; comparator: untreated control cells — Results > PC-PLC inhibition induces downmodulation of HER2 expression on the SKBr3 plasma membrane (S53); Figure 3 legend (S133)
Fluorescence assay of recombinant mouse ACE1 inhibition
Biochemical assay · Recombinant mouse ACE1 enzyme [3]
Recombinant mouse ACE1 enzyme was pre-incubated with various compound concentrations and assessed using a fluorescence-based enzymatic assay against a DMSO control. The reported IC50 ± SEM was 31.05 ± 10.82 µM.
Literature-Reported Treatment Conditions
- Treatment concentration
- various concentrations of compounds
- Exposure duration
- 15 min at room temperature; 30 min at room temperature
- Method
- pre-incubated
- Vehicle
- DMSO
Methods and source locations
Compound reported in the paper: D609
Evidence for D609 as the potassium form reported in the paper, not the free base/neutral form supplied as A11388; no salt equivalence, dose conversion or lot validation.
Results > Optimization of the HTS enzymatic assay (S25, S26); Results > Dose-response studies of the lead compounds against mACE (S40); Methods > Reagents for HTS assay (S196, S200); Methods > ACE enzymatic assay (S206, S208, S214); Table 1 (T1.h1, T1.r3)
Dose-response curves of the compounds obtained by fluorescence-based ACE enzymatic assay: Dose-response curves of the compounds obtained by fluorescence-based ACE enzymatic assay; comparator: DMSO control — Results > Dose-response studies of the lead compounds against mACE (S40); Table 1 (T1.h1, T1.r3)